The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).

Learn about the promising advance in prenatal treatment of spinal muscular atrophy, introducing a potential approach to suppress symptoms of the disorder in infants.

The evolution of functional assessments for spinal muscular atrophy (SMA) highlights the challenges of adapting pediatric ...

Spinal muscular atrophy (SMA) is a debilitating genetic condition that’s usually fatal by a few years of age. But an ...

Following the first-ever treatment for spinal muscular atrophy in the womb, physicians say a 2-year-old girl shows no signs ...

A new study from the University of Ottawa’s Faculty of Medicine sheds light on a potential breakthrough in treating muscle ...

A toddler was successfully treated for a rare genetic disease, spinal muscular atrophy, after world-first in-womb therapy.

After spending months in space Sunita Williams and Butch Wilmore are set to return to Earth But how will gravity impact their ...

Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

The revolutionary drug, called risdiplam, was taken by the mother during her 32nd week of pregnancy and is now part of the ...

Halle Berry opened up about her personal health during a new appearance, revealing that a herpes scare led to an important ...

If you often feel bloated fatigued or struggle with weak hair and nails despite eating enough protein your body might not be digesting it properly Read this article to know signs of protein indigestio ...